Blade, Yes, nice moves for KZIA and MGTA, and ONCT is also looking good.
Btw, are you still following HGEN? It looks interesting for a possible run-up ahead of their Phase 3 topline data in March. CYDY is their main competitor in the Covid 'cytokine storm' space, and the CYDY Phase 3 data announcement is now long overdue (trial ended mid-Jan). CYDY has shady management, and in addition to HGEN's own Phase 3 data, HGEN could get an added boost if the CYDY trial disappoints.
TA/charts are not generally as useful with bio stocks, but the HGEN chart looks like an impending breakout.
Also, just curious if you are still in TRIL? Thanks.
